Home / Market News / $ACAD
benzinga Corporate Catalyst Impact 55/100 ● negative

RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

Oct 8, 2026, 1:59 PM UTC · Primary ticker $ACAD

RBC Capital analyst Brian Abrahams reiterated an Outperform rating on Acadia Pharmaceuticals but slightly reduced the price target from $37 to $36. This indicates a continued positive outlook on the company's fundamentals, despite a minor adjustment to its valuation.

RBC Capital's analyst Brian Abrahams maintained an 'Outperform' rating for Acadia Pharmaceuticals, signaling a continued belief in the company's long-term potential. However, the price target was marginally lowered from $37 to $36. This small adjustment suggests a minor recalibration of valuation expectations, possibly due to updated financial models or market conditions, rather than a fundamental shift in the company's prospects. For traders, this is a relatively neutral event in the short term, as the core positive sentiment remains, but the slight price target reduction might temper immediate upside expectations. The long-term implication is that RBC still sees value in ACAD, but the growth trajectory might be slightly less aggressive than previously anticipated. The key risk is that other analysts might follow suit with similar minor price target reductions, creating a slight downward pressure on the stock.

$ACAD neutral Analyst rating maintained, price target slightly lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.